Copenhagen, Denmark; December 15, 2006 – Genmab A/S (CSE: GEN) announced today that Amgen has updated the development status of AMG 714 (formerly referred to as HuMax-IL15), on its website.  AMG 714 is a fully human monoclonal antibody directed against interleukin-15 (IL-15) that is being developed under an agreement with Genmab.  A Phase I clinical study of AMG 714 is now underway.  IL-15 blockade has potential utility in a wide variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, multiple sclerosis, and others.